Home > Drugs A-Z > Seb Prev

Seb Prev (Perrigo New York Inc)

Available Formats

Dosage Form Package Information Links
LIQUID 340 mL in 1 BOTTLE (45802-939-02) Label Information

Complete Seb Prev Information


    For Dermatologic Use Only

    Rx Only

    Not For Ophthalmic Or Intravaginal Use


    Each gram (0.95 mL) of SEB-Prevâ„¢ Wash contains 100 mg of Sulfacetamide Sodium, USP in a vehicle consisting of cocamidopropyl betaine, edetate disodium, methylparaben, PEG-6 caprylic/capric glycerides, PEG-60 almond glycerides, PEG-150 pentaerythrityl tetrastearate, purified water, sodium laureth sulfate, and sodium thiosulfate.

    Sulfacetamide sodium is C8H9N2Na03SH20 with a molecular weight of 254.24. Chemically, it is Acetamide N-[(4-aminophenyl)sulfonyl]-, monosodium salt, monohydrate, with the following structural formula:

    Image 1

    Sulfacetamide sodium is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform, and in ether.


    Sulfacetamide sodium exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There are no clinical data available on the degree and rate of systemic absorption of SEB-Prevâ„¢ Wash when applied to the skin or scalp. However, significant absorption

    of sulfacetamide sodium through the skin has been reported.

    The following in vitro data are available but their clinical significance is unknown. Organisms which show susceptibility to sulfacetamide sodium are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.


    SEB-Prevâ„¢ Wash is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.


    SEB-Prevâ„¢ Wash is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the product.


    Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sulfacetamide sodium topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome.


    General -

    Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. Hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. If SEB-Prevâ„¢ Wash produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. Under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur and appropriate observations and laboratory determinations should be performed.

    Information For Patients -

    Patients should discontinue SEB-Prevâ„¢ Wash if the condition becomes worse, or if a rash develops in the area being treated or elsewhere. SEB-Prevâ„¢ Wash also should be discontinued promptly and the physician notified if any arthritis, fever, or sores in the mouth develop.

    For external use only. Avoid contact with eyes and mucous membranes.

    Keep this and all medications out of reach of children. In case of accidental ingestion, call a physician or poison control center immediately (see OVERDOSAGE).

    Drug Interactions -

    SEB-Prevâ„¢ Wash is incompatible with silver preparations.

    Carcinogenesis, Mutagenesis, Impairment of Fertility -

    Long-term animal studies for carcinogenic potential have not been performed on SEB-Prevâ„¢ Wash to date. Studies on reproduction and fertility also have not been performed. One author detected chromosomal nondisjunction in the yeast, Saccharomyces cerevisiae, following application of sulfacetamide sodium. The significance of this finding to the topical use of sulfacetamide sodium in the human is unknown.


    Teratogenic effects:

    Pregnancy Category C -

    Animal reproduction studies have not been conducted with SEB-Prevâ„¢ Wash. It also is not known whether SEB-Prevâ„¢ Wash can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. SEB-Prevâ„¢ Wash should be given to a pregnant woman only if clearly needed.

    Nursing Mothers -

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SEB-Prevâ„¢ Wash is administered to a nursing woman.

    Pediatric Use -

    Safety and effectiveness in children under the age of 12 years have not been established.


    Reports of irritation and hypersensitivity to sulfacetamide sodium are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sulfacetamide sodium, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome has been reported (see WARNINGS).


    The oral LD50 of sulfacetamide in mice is 16.5 g/kg. The LD50 for topical administration of sulfacetamide has not been determined. Oral overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria, and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. In the event of overdosage, call a physician or poison control center; emergency treatment should be started immediately.

    Treatment: The patient should be induced to vomit, even if emesis has occurred spontaneously. Pharmacologic vomiting by the administration of ipecac syrup is a preferred method. However, vomiting should not be induced in patients with impaired consciousness. The action of ipecac is facilitated by physical activity and by the administration of eight to twelve fluid ounces

    of water. If emesis does not occur within 15 minutes, the dose of ipecac should be repeated. Precautions against aspiration must be taken, especially in infants and children. Following emesis, any drug remaining in the stomach may be absorbed by activated charcoal administered as a slurry with water. If vomiting is unsuccessful or contraindicated, gastric lavage should be performed. Isotonic and one-half isotonic saline are the lavage solutions of choice. Saline cathartics, such as milk of magnesia, draw water into the bowel by osmosis and, therefore, may be valuable for their action in rapid dilution of bowel content. After emergency treatment, the patient should continue to be medically monitored.

    Observe kidney function for up to 1 week and have the patient ingest copious amounts of fluid during this period. Mannitol infusions may be helpful at the first sign of oliguria. Alkalinization of the urine by ingestion of bicarbonate is very helpful in preventing crystallization of sulfa drug in the kidney.


    Seborrheic dermatitis including seborrhea sicca:

    Wash affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly and pat dry. Rinsing with plain water will remove any excess medication. Repeat application as described for eight to ten days. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently.

    Regular shampooing following SEB-Prevâ„¢ Wash is not necessary, but the hair should be shampooed at least once a week. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of SEB-Prevâ„¢ Wash should be reinitiated as at the beginning of treatment.

    Secondary cutaneous bacterial infections:

    Wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly and pat dry. Rinsing with plain water will remove any excess medication. Repeat application as described for eight to ten days. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less often.


    SEB-Prevâ„¢ Wash is available as follows:

    340 mL bottle (NDC 45802-939-02)

  • Click here to enter text.

    Store upright at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from freezing and excessive heat. The wash may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product.

    Occasionally, a slight yellowish discoloration may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration is readily removed by ordinary laundering without bleaches.

  • Click here to enter text.

    Image 2

    Rev. 02/12

    :4E200 RC J2

  • Principal Display Panel - 340 mL Label

    Rx Only

    SEB-Prevâ„¢ Wash

    (Sodium Sulfacetamide 10%)

    WARNING: For Dermatological Use Only. Not for Ophthalmic or Intravaginal Use.

    SEB-Prev (TM) Wash Sodium Sulfacetamide 10%) Label Image

    sodium sulfacetamide liquid
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:45802-939
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Inactive Ingredients
    Ingredient Name Strength
    WATER (UNII: 059QF0KO0R)  
    Product Characteristics
    Color WHITE (off-white) Score     
    Shape Size
    Flavor Imprint Code
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:45802-939-02 340 mL in 1 BOTTLE; Type 0: Not a Combination Product 07/28/2008 09/30/2018
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    Unapproved drug other 07/25/2008 09/30/2018
    Labeler - Perrigo New York Inc (078846912)